Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Recruitment Completed in Zalutumumab Head and Neck Cancer Pivotal Study10 Jun 2009
Capital Increase in Genmab as a Result of Employee Warrant Exercise10 Jun 2009
Genmab to Present at Three June Investor Conferences3 Jun 2009
Genmab Announces Partial Clinical Hold on Zalutumumab Studies3 Jun 2009
FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's Arzerra(TM) (Ofatumumab)29 May 2009
Interim Report 1st Quarter 200912 May 2009
Genmab Announces 2009 First Quarter Results12 May 2009
Genmab to Attend Merrill Lynch Conference
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
11 May 2009
Ofatumumab and R1507 Data to be Presented at ASCO11 May 2009
FDA Advisory Committee to Review Arzerra(TM) (Ofatumumab)4 May 2009
Articles of Association of Genmab A/S dated April 15, 200928 Apr 2009
Passing of Genmab A/S' Annual General Meeting15 Apr 2009
  • Previous
  • 1
  • More pages
  • 106
  • 107
  • 108
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863